RBC Capital Has Just Reaffirmed $147 Target Price Per Share on Charles River (NYSE:CRL) stock, While They’ve Also Reiterated Their “Outperform” Rating

November 9, 2018 - By Joshua Cleveland

Charles River Laboratories International, Inc. (NYSE:CRL) Logo

Investors sentiment increased to 1.43 in Q2 2018. Its up 0.30, from 1.13 in 2018Q1. It improved, as 14 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 45 funds opened positions while 107 raised stakes. 48.49 million shares or 9.51% more from 44.28 million shares in 2018Q1 were reported.

Personal Advsrs, a California-based fund reported 132,279 shares. Proshare Advsrs Ltd Liability reported 5,219 shares. Moreover, Cambridge Advsrs has 0.08% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 2,000 shares. Royal National Bank Of Canada holds 393,900 shares. Dimensional Fund Advsrs Ltd Partnership reported 0.02% in Charles River Laboratories International, Inc. (NYSE:CRL). Amer Intll Group reported 96,607 shares. Veritable Ltd Partnership accumulated 2,640 shares or 0.01% of the stock. Morgan Stanley invested in 0% or 61,382 shares. Amer Century Cos Inc holds 7,512 shares. 35,000 are held by State Of New Jersey Common Pension Fund D. Legal & General Group Public Limited Company reported 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL). Quantitative Investment Mgmt Limited Liability holds 10,600 shares. Primecap Mgmt Co Ca owns 424,100 shares for 0.04% of their portfolio. Ing Groep Nv has 7,339 shares for 0.02% of their portfolio. 5,880 were accumulated by Amp Ltd.

Since May 14, 2018, it had 0 buys, and 10 selling transactions for $7.90 million activity. $34,665 worth of Charles River Laboratories International, Inc. (NYSE:CRL) shares were sold by MASSARO GEORGE. Another trade for 11,126 shares valued at $1.34M was made by Molho Davide on Tuesday, July 17. Kochevar Deborah Turner also sold $502,799 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Tuesday, September 4. Another trade for 3,978 shares valued at $476,962 was made by Girshick Birgit on Tuesday, July 17.

Charles River (NYSE:CRL) Rating Reaffirmed

Research professionals at RBC Capital now has a $147 PT on Charles River (NYSE:CRL). RBC Capital and their recent PT would suggest a potential upside of 8.01 % from the company’s current price. The rating has been revealed in a research note on 8 November.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Among 10 analysts covering Charles River (NYSE:CRL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Charles River has $145 highest and $112 lowest target. $127.63’s average target is -6.22% below currents $136.1 stock price. Charles River had 11 analyst reports since June 15, 2018 according to SRatingsIntel. The rating was maintained by Argus Research with “Buy” on Monday, August 27. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Equal-Weight” rating given on Thursday, August 9 by Barclays Capital. As per Tuesday, September 11, the company rating was maintained by Morgan Stanley. The rating was upgraded by RBC Capital Markets to “Outperform” on Tuesday, July 17. On Tuesday, August 21 the stock rating was maintained by Credit Suisse with “Neutral”. The firm has “Outperform” rating given on Thursday, August 23 by Raymond James. Bank of America maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Monday, July 16. Bank of America has “Buy” rating and $125 target. The stock has “Overweight” rating by KeyBanc Capital Markets on Friday, June 15. Credit Suisse maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Tuesday, September 25. Credit Suisse has “Neutral” rating and $128 target. The firm has “Buy” rating by Jefferies given on Thursday, August 9.

The stock decreased 0.10% or $0.13 during the last trading session, reaching $136.1. About 547,008 shares traded or 36.89% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 18.17% since November 9, 2017 and is uptrending. It has outperformed by 2.55% the S&P500.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $6.54 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 51.57 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

More news for Charles River Laboratories International, Inc. (NYSE:CRL) were recently published by: Seekingalpha.com, which released: “Charles River Laboratories’ (CRL) CEO Jim Foster on Q3 2018 Results – Earnings Call Transcript” on November 07, 2018. Benzinga.com‘s article titled: “Earnings Scheduled For November 7, 2018” and published on November 07, 2018 is yet another important article.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.